Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke®

Author's Avatar
Aug 13, 2021

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the achievement of an important milestone of payor coverage for Gvoke – a ready-to-use glucagon for the treatment of severe hypoglycemia for adults and children with diabetes ages 2 and above. Today, approximately 91% of Medicare patients, 88% of commercially insured patients, and a growing number of Medicaid lives have unrestricted access to Gvoke.